Transurethral REsection and Single instillation mitomycin C Evaluation in bladder Cancer Treatment (RESECT)
Improving quality in TURBT surgery.
RESECT is a new GLOBAL prospective multi-centre international observational study starting in 2020.
CLICK ON THE RED BANNER BELOW TO PRE-REGISTER:
The RESECT study aims to understand and measure variation in operative practice, TURBT quality, SI MMC usage and early recurrence rates for patients undergoing TURBT surgery and to measure these against evidence based recommendations made in the EAU NMIBC guidelines.
Who can take part?
Anybody anywhere in the world who works in a centre performing TURBT can take part.
There is strong evidence which guides the optimal management of non muscle invasive bladder cancer (NMIBC), particularly in how the initial resection should be performed and in the use of single dose postoperative intravesical chemotherapy with Mitomycin-C (SI-MMC). We know that achieving a “good quality” NMIBC surgery results in improved accuracy of diagnosis and reduced recurrence rates. The European Association of Urology (EAU) guidelines include clear and easily measurable recommendations related to transurethral resection of bladder tumour (TURBT) and MMC use, based on best available evidence. Despite this there is anecdotal evidence that practice varies widely and this may impact on oncological outcomes.
Benefits of getting involved:
- Registration is simple and should avoid formal ethical approvals: In the UK the study will qualify as a “service evaluation” and will be exempt from needing ethical approval, although individual centres in other countries will have to follow local governance rules.
- Taking part is simple: you will be part of what could potential be the largest prospective audit of TURBT surgery ever performed.
- Use the database to record and track your own and your hospitals TURBT training, performance and outcomes.
- Anybody who works in a centre performing TURBT surgery can quickly and easily enter the data into our user-friendly online secure database.
- All contributors will receive Pubmed indexed collaborator authorship.
- The highest recruiting individuals will be invited onto the writing committee. The more patients recruited the higher up the collaborative list and you will gain preference for presentation of the study findings at conferences.
- Returns on this will be fast- our previous studies MIMIC and IDENTIFY are proof.
Proudly Supported by: